Virginia Kaklamani

21PUBLICATIONS
107CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Economic models and forecastingMolecular targetsPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Oct 13, 2026
Differential impact of tumor-derived ESR1 mutations on elacestrant benefit in metastatic breast cancer.

|Aug 24, 2026
Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.

|Nov 14, 2025
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.

Hope S Rugo, Virginia Kaklamani, Heather McArthur

|May 21, 2025
Treatment Patterns of Goserelin 3.6 mg Once Every 4 Weeks and 10.8 mg Once Every 12 Weeks in Women With Breast Cancer: A Real-World Analysis of Patients in the United States.

Kelly E McCann, Virginia Kaklamani, Noran Osman

|Apr 15, 2025
Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.

Ranjit Banwait, Heidi Ko, Joel Michalek

|Mar 06, 2025
Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study.

Kelly E McCann, Noran Osman, Joan Cannon

Pageof 4

Frequent Collaborators

4 joint publications

Aditya Bardia

3 joint publications

Marisa Weiss

3 joint publications

Rowen Chlebowski

3 joint publications

Tomer Wasserman